Since its founding, Calico has built deep expertise in the biology of aging and created platforms that draw on large human data cohorts, powered by a proprietary machine learning platform and Google-scale computing. And the company is now using this foundation to map aging pathways, identify druggable targets, and move forward emerging therapeutic opportunities.
In a Q&A with Nature Reviews Drug Discovery, Philip Kym, Ph.D., Head of Drug Discovery, discusses Calico’s evolution from a focus on the foundational biology of aging to an organization with multiple clinical programs and the capabilities to develop therapeutics on its own or in collaboration with its partners.
In the interview, Phil points to the role of large human data cohorts and computation, including Calico’s work with UK Biobank, in uncovering new mechanisms of aging and disease. These platforms are now mature enough to generate promising therapeutic opportunities that may move into development and, ultimately, into the clinic. Today, Calico has five assets in clinical development and more than 20 early-stage programs.
The full interview can be found on the Nature Reviews Drug Discovery website.